Detail akcie Amgen Inc online

Business Summary: Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Amgen Inc revenues increased 10% to $36.75B. Net income increased 89% to $7.71B. Revenues reflect Product Sales increase of 10% to $35.15B, Other revenues increase of 15% to $1.6B. Net income benefited from Interest expense, net decrease of 13% to $2.76B (expense). Dividend per share increased from $9.00 to $9.52. Basic Earnings per Share excluding Extraordinary Items increased from $7.62 to $14.33.